



## **Cytomedix To Host Third Quarter And Nine Months 2009 Financial Results Conference Call On Thursday, November 12, 2009**

**ROCKVILLE, Md. (October 30, 2009)** – Cytomedix, Inc. (NYSE Amex: GTF), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that the Company will release financial results for the third quarter and nine months ended September 30, 2009, following the close of the market on Wednesday, November 11, 2009.

Martin Rosendale, Chief Executive Officer, and Andrew Maslan, Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time on Thursday, November 12, 2009 to discuss third quarter and nine months 2009 financial results and to answer questions.

Shareholders and other interested parties may participate in the conference call by dialing 800-299-0433 (domestic) or 617-801-9712 (international) and entering passcode 29310211 a few minutes before 10:00 a.m. ET on Thursday, November 12, 2009. The call will also be broadcast live on the Internet at [www.streetevents.com](http://www.streetevents.com), [www.fulldisclosure.com](http://www.fulldisclosure.com) and [www.cytomedix.com](http://www.cytomedix.com).

A replay of the conference call will be accessible two hours after its completion through November 19, 2009 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 71771840. The call will also be archived for 90 days at [www.streetevents.com](http://www.streetevents.com), [www.fulldisclosure.com](http://www.fulldisclosure.com) and [www.cytomedix.com](http://www.cytomedix.com).

### **About Cytomedix**

Cytomedix develops, sells and licenses regenerative biological therapies including the AutoloGel™ System, a device for the production of Platelet Rich Plasma ("PRP") gel derived from the patient's own blood. The AutoloGel™ System is cleared by the U.S. Food and Drug Administration for use on a variety of exuding wounds. The Company is pursuing a multi-faceted strategy to penetrate the chronic wound market with its AutoloGel™ System. The Company is also moving forward with the development of other product candidates in its pipeline. Most notably is its CT-112 product, an anti-inflammatory peptide that has shown promise in preclinical testing. Additional information regarding Cytomedix is available at [www.cytomedix.com](http://www.cytomedix.com).

### **Safe Harbor Statement**

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, viability and effectiveness of the Company's sales approach and overall marketing

strategies, the outcome of development or regulatory review of CT-112, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, its ability to successfully commercialize its product in Japan under the terms of the license agreement, and Cytomedix's ability to execute on its strategy to market the AutoloGel(tm) System as contemplated. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

**Contacts:**

Cytomedix, Inc.

David Jordan, Executive Board Member

Martin Rosendale, CEO

(240) 499-2680

Lippert/Heilshorn & Associates

Anne Marie Fields

[afields@lhai.com](mailto:afields@lhai.com)

(212) 838-3777

# # #